Why is DSIP discussed in an obesity review?

The proposed connection runs through glucocorticoids and circadian timing, which link to adipose biology — not through sleep.

Glucocorticoid-induced leucine zipper, a protein driven by glucocorticoid signalling with roles in immune regulation and adipocyte biology.

How strong is the evidence?

It is a hypothesis paper, and its title ends in a question mark. It assembles existing observations rather than adding new data.

DSIP (Delta Sleep-Inducing Peptide)

A Question Mark in the Title Is Doing Real Work

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Gimble and colleagues published on delta sleep-inducing peptide and glucocorticoid-induced leucine zipper as potential links between circadian mechanisms and obesity in Obesity Reviews in 2009. The title ends in a question mark, which accurately describes what is being proposed.

Key facts

Study: Gimble 2009 (PMID 19849801)
Journal: Obes Rev, November 2009
Other molecule: GILZ — glucocorticoid-induced leucine zipper
Proposed link: Circadian mechanisms and obesity
Article type: Hypothesis, framed as a question
Common thread: Glucocorticoid regulation

Why DSIP appears in an obesity journal at all

Because the proposed connection runs through glucocorticoids and circadian timing rather than through sleep. Cortisol follows a strong daily rhythm, influences adipose biology, and connects to metabolic regulation. A substance tracking that axis has a route into obesity research that has nothing to do with the effect it was named for.

What GILZ is

Glucocorticoid-induced leucine zipper is a protein whose expression is driven by glucocorticoid signalling, and which participates in immune regulation and adipocyte biology. It is a well-characterised downstream effector of the same hormonal system, which is what makes it a reasonable thing to consider alongside a molecule associated with the adrenal axis.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

Why the question mark matters

The title asks whether these are potential links rather than asserting that they are. That is the correct register for a hypothesis paper, and it is the element most likely to be lost when such work is cited. A proposal in the literature is a suggestion about where to look, not a finding.

What a hypothesis paper contributes

It assembles existing observations into a testable structure. That has genuine value — it directs subsequent work and identifies what evidence would settle the question. It contributes no new experimental data, and its standing depends entirely on what follows it.

How this fits the wider DSIP picture

It is a further instance of the compound appearing in association with the glucocorticoid and circadian systems rather than with sleep machinery directly. Whether that reflects something real about the molecule, or about what antibodies raised against it detect, is the question running underneath the entire literature.

What is not claimed

Anything about obesity, circadian rhythm, sleep or metabolism in any person. This describes a 2009 hypothesis paper. DSIP holds no marketing authorisation anywhere and material supplied here is for laboratory research only.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why is DSIP discussed in an obesity review?: The proposed connection runs through glucocorticoids and circadian timing, which link to adipose biology — not through sleep.
What is GILZ?: Glucocorticoid-induced leucine zipper, a protein driven by glucocorticoid signalling with roles in immune regulation and adipocyte biology.
How strong is the evidence?: It is a hypothesis paper, and its title ends in a question mark. It assembles existing observations rather than adding new data.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum